ASI was founded by two proven medical device entrepreneurs, Tim Fischell, MD and David Fischell, PhD. With executive experience in both biopharmaceutical and medical device companies, Vartan Ghazarossian, PhD, is uniquely positioned to lead the development of ASI's novel device-chemistry-based therapy. Dr. Steven Almany of BioStar Ventures, a member of ASI's Board of Directors, commented: 'The therapeutic potential of perivascular renal denervation is very attractive, and we are very pleased to invest in ASI's team as they develop their unique approach.'
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/19/12 | $5,300,000 | Series A |
BioStar Ventures Charter Capital Partners | undisclosed |
| 01/03/19 | $77,000,000 | Series D |
BioStar Ventures Charter Capital Partners Gilde Healthcare Partners Novus Biotechnology | undisclosed |
